WilmerHale represented the underwriters in the public offering of 3,884,158 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 1,633,663 additional shares of common stock, and pre-funded warrants to purchase 8,640,594 shares of common stock by Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD). Kymera received approximately $316.2 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. The offering priced on January 4, 2024 and closed on January 9, 2024.

The WilmerHale team representing the underwriters included Lisa Firenze, Ryan Brewer, and Milan Kumar with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar on intellectual property matters.